f*1
2 楼
The drug maker reported positive interim data from a Phase 2 clinical study
evaluating poziotinib in EGFR Exon 20 Mutant Non-Small-Cell Lung Cancer (
NSCLC).
evaluating poziotinib in EGFR Exon 20 Mutant Non-Small-Cell Lung Cancer (
NSCLC).
相关阅读